Financials

News Ideas Technicals

6932 fundamentals

Overview Statements Statistics Dividends Earnings Revenue

An in-depth look to MERCURY BIOPHARMACEUTICAL CORPORATI operating, investing, and financing activities

6932 free cash flow for H2 23 is -25.38 M TWD. For 2023, 6932 free cash flow was -55.07 M TWD and operating cash flow was -42.15 M TWD.

‪0.00‬

Cash from operating activities

Cash from investing activities

Cash from financing activities

Income statement Balance sheet Cash flow

Currency: TWD

TTM

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—

YoY growth

—

—

—

—

—

—

—

—